Literature DB >> 1827033

Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters.

R C Snyder1, R Ray, S Blume, D M Miller.   

Abstract

The c-myc protooncogene plays an important role in the regulation of cellular proliferation. Mithramycin, a DNA binding antibiotic which binds G-C-rich DNA, inhibits c-myc expression in both differentiating and nondifferentiating cells. The G-C-rich nature of the c-myc promoter suggests that mithramycin may act by directly inhibiting promoter function. The mithramycin binding sites in the c-myc promoter regions were determined by DNAse I footprinting. Particularly prominent mithramycin binding is noted in the regions just 5' of the P1 and P2 promoter TATA boxes. Gel retardation experiments performed in the presence of mithramycin demonstrate that drug binding can prevent the formation of discrete complexes between HeLa cell nuclear proteins and c-myc promoter DNA fragments. Mithramycin also directly blocks the binding of the transcription factor Sp1 to the P1 promoter region. In vitro run-off transcription demonstrates that mithramycin can completely inhibit the in vitro function of both the P1 and P2 promoters. These data suggest that mithramycin inhibits transcription of the c-myc protooncogene by blocking the binding of important regulatory factors, thus preventing formation of the c-myc transcription initiation complex.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827033     DOI: 10.1021/bi00231a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  40 in total

1.  Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.

Authors:  Sara Previdi; Anastasia Malek; Veronica Albertini; Cristina Riva; Carlo Capella; Massimo Broggini; Giuseppina M Carbone; Jurgen Rohr; Carlo V Catapano
Journal:  Gynecol Oncol       Date:  2010-05-08       Impact factor: 5.482

2.  Regulation of mGluR1 expression in human melanocytes and melanoma cells.

Authors:  Hwa Jin Lee; Brian A Wall; Janet Wangari-Talbot; Suzie Chen
Journal:  Biochim Biophys Acta       Date:  2012-07-05

3.  Premithramycinone G, an early shunt product of the mithramycin biosynthetic pathway accumulated upon inactivation of oxygenase MtmOII.

Authors:  Mohamed S Abdelfattah; Jürgen Rohr
Journal:  Angew Chem Int Ed Engl       Date:  2006-08-25       Impact factor: 15.336

4.  Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter.

Authors:  S W Blume; J E Gee; K Shrestha; D M Miller
Journal:  Nucleic Acids Res       Date:  1992-04-11       Impact factor: 16.971

Review 5.  Drugging the undruggable: transcription therapy for cancer.

Authors:  Chunhong Yan; Paul J Higgins
Journal:  Biochim Biophys Acta       Date:  2012-11-09

6.  Targeting of the HIV-1 long terminal repeat with chromomycin potentiates the inhibitory effects of a triplex-forming oligonucleotide on Sp1-DNA interactions and in vitro transcription.

Authors:  N Bianchi; C Rutigliano; M Passadore; M Tomassetti; L Pippo; C Mischiati; G Feriotto; R Gambari
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

7.  Zip14 expression induced by lipopolysaccharides in macrophages attenuates inflammatory response.

Authors:  Ahmed Sayadi; Anh-Tuan Nguyen; Frederic A Bard; Emilie A Bard-Chapeau
Journal:  Inflamm Res       Date:  2012-10-02       Impact factor: 4.575

8.  Effect of complex formation between Zn2+ ions and the anticancer drug mithramycin upon enzymatic activity of zinc(II)-dependent alcohol dehydrogenase.

Authors:  Suman Das; Pukhrambam Grihanjali Devi; Sudipta Pal; Dipak Dasgupta
Journal:  J Biol Inorg Chem       Date:  2004-11-18       Impact factor: 3.358

9.  FOSL1 controls the assembly of endothelial cells into capillary tubes by direct repression of αv and β3 integrin transcription.

Authors:  Sandrine Evellin; Federico Galvagni; Alessio Zippo; Francesco Neri; Maurizio Orlandini; Danny Incarnato; Daniela Dettori; Stefanie Neubauer; Horst Kessler; Erwin F Wagner; Salvatore Oliviero
Journal:  Mol Cell Biol       Date:  2013-01-14       Impact factor: 4.272

10.  Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.

Authors:  Yang Liu; Joseph M Eckenrode; Yinan Zhang; Jianjun Zhang; Reiya C Hayden; Annet Kyomuhangi; Larissa V Ponomareva; Zheng Cui; Jürgen Rohr; Oleg V Tsodikov; Steven G Van Lanen; Khaled A Shaaban; Markos Leggas; Jon S Thorson
Journal:  J Med Chem       Date:  2020-11-16       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.